Jonathan Cebon
YOU?
Author Swipe
View article: Supplementary Figure S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 3. Analysis of immune cell populations in all samples
View article: Data from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Data from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Purpose:Acquired or de novo resistance to immune checkpoint inhibitors occurs in the majority of advanced non–small cell lung cancers. There is an unmet need to improve outcomes for patients with this condition. Oncolytic viruses re…
View article: Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 1. CAVATAK trial inclusion and exclusion criterias
View article: Supplementary Table S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 4: Systemic therapy received by each patient prior to recruitment into the trial.
View article: Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 5. Functional markers expressed in CD8+ T cells in gPFS patients
View article: Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 5. CAVATAK samples: time between biopsies and biopsy sites.
View article: Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Figure 2. Tumor cell characteristics at baseline and on treatment in gPFS and loPFS patients
View article: Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial Open
Supplementary Table 2. Representativeness of study participants
View article: Pregnancy-associated plasma protein-A drives melanoma metastasis and immune evasion via IGF signaling
Pregnancy-associated plasma protein-A drives melanoma metastasis and immune evasion via IGF signaling Open
Background Melanoma is one of the most common cancers diagnosed during pregnancy. Pregnancy-associated plasma protein-A (PAPPA) is a secreted metalloproteinase that increases local insulin-like growth factor (IGF) bioavailability via prote…
View article: Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy Open
Lung cancers and melanomas have many somatically mutated self-proteins that would be expected to trigger an immune rejection response, yet therapeutic responses can only be induced in a subset of patients. Here, we investigated the possibi…
View article: Figure S2 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Figure S2 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Open
Figure S2
View article: Figure S1 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Figure S1 from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Open
Figure S1
View article: Data from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Data from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Open
Purpose:Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-…
View article: Supplementary Data from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Supplementary Data from Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Open
Clean version
View article: A gut microbial signature for combination immune checkpoint blockade across cancer types
A gut microbial signature for combination immune checkpoint blockade across cancer types Open
Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte protein 4 (CTLA-4) can induce remarkable, yet unpredictable, responses across a variety of cancers. Studies suggest that there is …
View article: Supplementary Table S3 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S3 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S3
View article: Supplementary Table S5 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S5 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S5
View article: Supplementary Table S6 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S6 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S6
View article: Data from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Data from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Antigen recognition by CD8+ T cells is governed by the pool of peptide antigens presented on the cell surface in the context of HLA class I complexes. Studies have shown not only a high degree of plasticity in the immunopeptidom…
View article: Data from Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma
Data from Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma Open
Metastasis of human tumors to lymph nodes (LN) is a universally negative prognostic factor. LN stromal cells (SC) play a crucial role in enabling T-cell responses, and because tumor metastases modulate their structure and function, this in…
View article: Supplementary Table S3 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S3 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S3
View article: Supplementary Figures and Tables from Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma
Supplementary Figures and Tables from Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma Open
Supplementary Figures 1-6 and Tables 1-7
View article: Supplementary Figures from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Figures from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Supplementary Figures S1-S10
View article: Supplementary Table S5 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S5 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S5
View article: Supplementary Table S6 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S6 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S6
View article: Supplementary Table S4 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S4 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S4
View article: Data from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Data from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Antigen recognition by CD8+ T cells is governed by the pool of peptide antigens presented on the cell surface in the context of HLA class I complexes. Studies have shown not only a high degree of plasticity in the immunopeptidom…
View article: Supplementary Table S4 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S4 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S4
View article: Data from Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma
Data from Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma Open
Metastasis of human tumors to lymph nodes (LN) is a universally negative prognostic factor. LN stromal cells (SC) play a crucial role in enabling T-cell responses, and because tumor metastases modulate their structure and function, this in…
View article: Supplementary Table S2 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma
Supplementary Table S2 from Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma Open
Table S2